Scientific Assessment of the Anti-Inflammatory and Wound Healing Potential of *Campanula lyrata* subsp. *lyrata*, A Turkish Folk Remedy

Ipek SUNTAR1, Esra KUPELI AKKOL1*, Tuba MERT GONENC2, Tugce FAFAL ERDOGAN2, Hikmet KELES3, Bijen KIVCAK2

1Gazi University, Faculty of Pharmacy, Department of Pharmacognosy, Etiler 06330 Ankara, TURKEY, 2 Ege University, Faculty of Pharmacy, Department of Pharmacognosy 35100 Izmir, TURKEY, 3 Afyon Kocatepe University, Faculty of Veterinary Medicine, Department of Pathology, 03200 Afyonkarahisar, TURKEY

The aim of the present study is to evaluate the anti-inflammatory and wound healing activities of the extracts prepared from the aerial parts of *Campanula lyrata* Lam. subsp. *lyrata* (Campanulaceae) by using in vivo methods in order to confirm the traditional utilization. n-Hexane, diethyl ether, ethyl acetate (EtOAc), methanol (MeOH) and aqueous extracts were separately prepared from the air-dried and powdered plant materials. Carrageenan-, and serotonin- induced hind paw edema, 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse ear edema and acetic acid-induced increase in capillary permeability models were employed in mice for the anti-inflammatory activity assessment. Wound-healing activity was investigated by using incision and excision wound models along with hydroxyproline determination and histopathological analyses. MeOH extract displayed significant anti-inflammatory effect in the carrageenan- and serotonin- induced hind paw edema model and in acetic acid-induced increase in capillary permeability model with the values of 25.3, 27.8 and 31.8%, respectively. MeOH extract was also found to have significant wound healing potential in the incision and excision wound models with the values of 26.9 and 39.6%, respectively. MeOH extract ointment treated group tissues also showed enhanced hydroxyproline content. The present study confirms the anti-inflammatory and wound healing activities of *C. lyrata* subsp. *lyrata*.

Key words: *Campanula* spec., *Campanulaceae*, Carrageenan, Excision, Incision, Serotonin, TPA

Correspondence: E-mail: esrak@gazi.edu.tr; Tel: +90 312 2023185.
INTRODUCTION

The genus *Campanula* L. (Campanulaceae) is represented by 113 native species, 95 of which are growing in Turkish flora and 61 of them are endemic to Turkey (1). *Campanula* species have been used to treat various diseases such as tonsillitis, laryngitis, bronchitis, and warts in traditional medicine (2). In Turkey, *Campanula* species are known as “çançığı” and have been used for wound healing and for the treatment of inflammatory diseases (3). *Campanula* species possess stimulant, refreshing, antiallergic, antiphlogistic, antioxidant, spasmyloytic, antiviral, cytotoxic, antinociceptive and antimicrobial properties and are used as an emetic (4-6). However, there are no reports on the anti-inflammatory and wound healing activities of *Campanula lyrata* Lam. subsp. lyrata.

*Campanula* species contain a variety of chemical compounds such as polyphenols (flavonoid aglycones and their glycosides, phenolic acids and their esters, as well as phenylpropanoid derivates), steroids, triterpenes and polyacetylenes (5,7-9).

In this study, the anti-inflammatory and wound healing activities of the *n*-hexane, diethyl ether, EtOAc, MeOH and aqueous extracts obtained from *C. lyrata* subsp. *lyrata* were evaluated by using in vivo experimental models.

EXPERIMENTAL

Plant material

*Campanula lyrata* Lam. subsp. *lyrata* was collected from Izmir-Çeşme in May, 2009 and identified by B. Kıvçak from Ege University. The voucher specimen (No: 1310) is deposited in the herbarium of the Faculty of Pharmacy, Ege University, Izmir.

Preparation of the plant extract

*n*-Hexane, diethyl ether, EtOAc, MeOH and aqueous extracts were separately prepared from 20 g batches of the air-dried and powdered plant materials by extracting with 200 mL solvent at room temperature for 24 h. Then the solvents were evaporated to dryness in vacuo (60°C). The yields of *n*-hexane, diethyl ether, EtOAc, MeOH and aqueous extracts were 0.78, 0.98, 5.09, 8.32, and 9.80%, respectively. All the extracts were stored at -20°C.

Pharmacological procedures

Animals

Male Sprague-Dawley rats (160-180 g) and Swiss albino mice (20-25 g) were purchased from Kobay Experimental Animals Laboratory, Ankara, Turkey.

The animals were left for 3 days for acclimatization into animal room conditions and were maintained on standard pellet diet and water *ad libitum*. For the anti-inflammatory activity assessment the food was withdrawn on the day before the experiment, but free access to water was allowed. A minimum of six rats were used in each group for wound healing experiments, while ten mice were used in anti-inflammatory studies. The present study was performed according to the international rules considering the animal experiments and biodiversity rights. (Gazi University Ethical Council Project Number: G.U.ET-08.037).

Preparation of test samples for bioassay

For the anti-inflammatory test model, samples were given orally to test animals after suspending in a mixture of distilled water and 0.5% sodium carboxymethyl cellulose (CMC). The control group animals received the same experimental handling as those of the test groups except that the drug treatment was replaced with appropriate volumes of the dosing vehicle. Indomethacin (10 mg/kg) in 0.5% CMC was used as a reference drug.

For the assessment of wound-healing activity, an ointment prepared with the test materials were topically applied onto the wounded area of test animals. The test ointments were prepared by mixing the extracts or with a mixture of ointment base consisting of glycol stearate: propylene glycol and liquid paraffin (3:6:1) in a mortar thoroughly. Treatments were started immediately after the production of wound by daily application of the test ointments on the wounded area. The control group animals were topically treated with blank vehicle base, while the animals in negative control group
were not treated with any product. Madecassol® (Bayer) (0.5 g) was used topically as the reference drug.

**Anti-inflammatory activity**

**Carrageenan-induced hind paw edema model**

Carrageenan-induced hind paw edema model was used for determination of anti-inflammatory activity (10). Sixty min after oral administration of a test sample or dosing vehicle, each mouse was injected with freshly prepared suspension of carrageenan (0.5 mg/25 µL) in physiological saline (154 mM NaCl) into subplantar tissue of the right hind paw. Saline solutions (25 µL) were injected into that of the left hind paw. Paw edema was then measured in every 90 min during 6 h after induction of inflammation. The difference in footpad thickness was measured by gauge calipers (Ozaki Co., Tokyo, Japan). Mean values of treated groups were compared with those of the control group and analyzed by using statistical methods. Indomethacin (10 mg/kg) was used as the reference drug.

**Serotonin-induced hind paw edema model**

The method of Kasahara et al. (1985) was used (11). Sixty min after oral administration of test sample or dosing vehicle each mouse was injected with serotonin (serotonin creatinin sulfate, Merck, Art. 7768) in Tyrode’s solution (0.5 µg/5 µL) into subplantar tissue of the right hind paw and 5 µL of Tyrode’s solution into that of the left as secondary control. Measurements were done and evaluated as described above in every 6 min during 30 min.

**TPA-induced mouse ear edema**

Each mouse received 2.5 µg of TPA dissolved in 20 µL of EtOH 70%. This was applied by an automatic pipette in 20 µL volumes to both anterior and posterior surfaces of the right ear. The left ear (control) received the same volume of solvent (EtOH 70%), simultaneously with TPA. Indomethacin (0.5 mg/ear) was used as reference drug. For the evaluation of the activity, two different measurements were taken as given below.

The thickness of each ear was measured 4 h after induction of inflammation using gauge calipers (Ozaki Co., Tokyo, Japan). The edema was expressed as the difference between the right and left ears due to TPA application and consequently inhibition percentage was expressed as a reduction thickness with respect to the control group.

After 4 h of the administration the animals were sacrificed. Discs of 6 mm diameter were removed from each ear and weighed in balance. The swelling was estimated as the difference in weight between the punches from right and left ears and expressed as an increase in the ear thickness (12).

**Acetic acid-induced increase in capillary permeability**

Effect of the test samples on increased vascular permeability induced by acetic acid in mice was determined according to Whittle Method with some modifications (13). Each test sample was administered orally to a group of 10 mice in 0.2 mL/20 g body weight. Thirty min after administration, tail of each animal was injected with 0.1 mL of 4% Evans blue in saline solution (i.v.) and waited for 10 min. Then, 0.4 mL of 0.5% (v/v) AcOH was injected i.p. After 20 min. incubation, mice were killed by dislocation of the neck, and the visera were exposed and irrigated with distilled water, which was then poured into 10 mL volumetric flasks through glass wool. Each flask was made up to 10 mL with distilled water, 0.1 mL of 0.1N NaOH solution was added to the flask, and the absorption of the final solution was measured at 590 nm (Beckmann Dual Spectrometer; Beckman, Fullerton, CA, USA). A mixture of distilled water and 0.5% CMC was given orally to control animals, and they were treated in the same manner as described above.

**Acute toxicity**

Animals employed in the carrageenan-induced paw edema experiment were observed during 48 h and morbidity or mortality was recorded.

**Gastric-ulcerogenic effect**

After the employment of serotonin-induced hind paw edema model, mice were sacrificed and the stomachs of each mouse were removed. Then the abdomen was opened.
through the greater curvature and examined under dissecting microscope for lesions or bleedings.

**Wound healing activity**

**Incision wound model**

All the animals were anaesthetized with 0.05 cm³ Xylazine (2% Alfazine®) and 0.15 cm³ Ketamine (10% Ketasol®) and the back hair of the rats was shaved by using a shaving machine and cleaned with 70% alcohol. Two 5 cm length linear-paravertebral incisions were made with a sterile blade through the skin at the distance of 1.5 cm from the dorsal midline on each side. Three surgical interrupted sutures were placed each 1 cm apart.

The test ointments and the reference drug (Madecassol®) were topically applied on the dorsal wounds once daily for 9 days. All the sutures were removed on the last day and tensile strength of previously wounded and treated skin was measured by using a tensiometer (Zwick/Roell Z0.5, Germany) (14).

**Excision wound model**

This model was used to monitor wound contraction and wound closure time. Each mouse was anaesthetized with 0.02 cm³ Xylazine (2% Alfazine®) and 0.08 cm³ Ketamine (10% Ketasol®). The back hairs were depilated by shaving. A circular wound was created on the dorsal interscapular region of each animal by excising the skin with a 5 mm biopsy punch (Nopa instruments, Germany); wounds were left open. Test samples, the reference drug (Madecassol®), Bayer and the vehicle ointments were applied topically once a day till the wound completely healed. The progressive changes in wound area were monitored by a camera (Fuji, S20 Pro, Japan) every other day. Later on, wound area was calculated by using AutoCAD program. A specimen sample of tissue was isolated from the healed skin of each group of mice for the histopathological examination (14).

**Histopathology**

The skin specimens from each group were collected at the end of the experiment (on day 12). Samples were fixed in 10% buffered formalin, processed and blocked with paraffin and then sectioned into 5 micrometer sections and stained with hematoxylin & eosin (HE) and Van Gieson (VG) stains. The tissues were examined by light microscope (Olympus CX41 attached Kameram® Digital Image Analyze System) and graded as mild (+), moderate (+++) and severe (++++) for epidermal or dermal re-modeling. Re-epithelization or ulcer in epidermis; fibroblast proliferation, mononuclear and/or polymorphonuclear cells, neo-vascularization and collagen deposits in dermis were analyzed to score the epidermal or dermal re-modeling. Van Gieson stained sections were analyzed for collagen deposition. At the end of the examination, all the wound healing processes were combined and staged for wound healing phases as inflammation, proliferation, and re-modeling in all groups.

**Hydroxyproline estimation**

Tissues were dried in hot air oven at 60-70°C until consistent weight was achieved. Afterwards, samples were hydrolyzed with 6 N HCl for 3 h at 130°C. The hydrolyzed samples were adjusted to pH 7 and subjected to chloramin T oxidation. The colored adduct formed with Ehrlich reagent at 60°C was read at 557 nm. Standard hydroxyproline was also run and values reported as µg/mg dry weight of tissue (15).

**Statistical Analysis**

Data obtained from animal experiments were expressed as the mean standard error (± SEM). Statistical differences between the treated and the control groups were evaluated by ANOVA and Students-Newman-Keuls post-hoc tests. P < 0.05 was considered to be significant [*p < 0.05; ** p < 0.01; *** p < 0.001]. Histopathologic data were considered to be nonparametric; therefore, no statistical tests were performed.

**RESULTS AND DISCUSSION**

The anti-inflammatory activity of the extracts prepared from *C. lyrata* subsp. *lyrata* were evaluated by using the in vivo experimental methods *i.e.* carrageenan- and serotonin-
induced hind paw edema, TPA-induced mouse ear edema and acetic acid-induced increase in capillary permeability models at doses of 100 and 200 mg/kg. The results of the anti-inflammatory activity experiments were presented in Tables 1-4. MeOH extract displayed significant anti-inflammatory effect on carrageenan-induced hind paw edema model with the inhibition value of 25.3% at 180 min (Table 1). The carrageenan-induced paw edema model is a biphasic event, involves several chemical mediators such as histamine, serotonin, bradykinin, and prostaglandins (16). In the early phase (90-180 min) of the inflammation histamine, serotonin and similar substances are released. The later phase (270-360 min) kinin-like substances such as prostaglandins, proteases and lysosome are activated (17). According to the results of the present study, the MeOH extract of *C. lyrata* subsp. *lyrata* exerted anti-inflammatory activity in the early phase of inflammation. Serotonin-induced hind paw edema model was employed to clarify the the anti-inflammatory mechanism of the extracts. *C. lyrata* subsp. *lyrata* displayed significant inhibition value of 24.8% at 12 min at 200 mg/kg dose (Table 2). However, none of the extracts, including the MeOH extract, were found to be effective in the TPA-induced ear edema model (Table 3) which is closely related with the infiltration of macrophages and neutrophil, the induction of TNF-α and IL-1 (18). On the other hand, MeOH extract was found to be active on the acetic acid-induced increase in capillary permeability model with the remarkable inhibition value of 31.8% (Table 4). In all of the anti-inflammatory activity models, reference drug indomethacin exerted high activity potential.

In the present study, *in vivo* wound-healing

### Table 1. Effect of the extracts from *Campanula lyrata* subsp. *lyrata* on carrageenan-induced paw edema model in mice

| Material      | Dose (mg/kg) | 90 min | 180 min | 270 min | 360 min |
|---------------|--------------|--------|---------|---------|---------|
| Control       |              | 49.2±3.5 | 50.2±2.8 | 51.7±2.9 | 56.7±3.0 |
| *n*-Hexane extract | 100          | 40.6±3.1 | 48.6±3.0 | 55.4±3.2 | 54.6±3.5 |
|               |              | (2.0)   | (3.2)   | -       | (3.7)   |
|               | 200          | 45.2±3.3 | 40.6±2.5 | 42.6±2.4 | 49.0±3.6 |
|               |              | (8.1)   | (19.1)  | (17.6)  | (13.6)  |
| Diethyl ether extract | 100          | 48.7±3.0 | 49.6±2.9 | 46.4±3.6 | 51.3±3.7 |
|               |              | (1.0)   | (1.2)   | (10.3)  | (9.5)   |
|               | 200          | 42.6±2.9 | 44.6±2.4 | 48.8±3.9 | 55.3±3.8 |
|               |              | (13.4)  | (11.2)  | (5.6)   | (2.5)   |
| EtOAc extract | 100          | 48.6±2.7 | 45.4±2.9 | 45.7±2.6 | 49.9±3.5 |
|               |              | (1.2)   | (9.6)   | (11.6)  | (11.9)  |
|               | 200          | 42.6±3.3 | 53.6±3.9 | 43.3±2.5 | 52.4±2.7 |
|               |              | (13.4)  | -       | (16.2)  | (7.6)   |
| MeOH extract  | 100          | 40.6±3.7 | 43.7±2.7 | 50.4±3.1 | 53.6±2.8 |
|               |              | (17.5)  | (12.9)  | (2.5)   | (5.5)   |
|               | 200          | 37.5±3.2 | 37.5±2.8 | 49.1±3.5 | 52.4±3.1 |
|               |              | (23.8)  | (25.3)* | (5.0)   | (7.6)   |
| Aqueous extract | 100         | 41.8±3.6 | 55.6±3.5 | 50.7±3.6 | 50.3±2.9 |
|               |              | (15.0)  | -       | (1.9)   | (11.3)  |
|               | 200          | 39.6±2.8 | 50.6±2.7 | 58.8±3.8 | 57.4±3.7 |
|               |              | (19.5)  | -       | -       | -       |
| Indomethacin  | 10           | 30.8±2.0 | 34.6±2.1 | 37.6±1.9 | 32.7±2.0 |
|               |              | (37.4)**| (31.1)**| (27.3)* | (42.3)**|

S.E.M.: Standard error of the mean
* p<0.05. **p<0.01. *** p<0.001 significant from the control
effect of the extracts of *C. lyrata* was also evaluated. Ointment formulation prepared from the MeOH extract exerted a significant wound healing activity on the incision wound model with the tensile strength value of 26.9% at day 10 and on the excision wound model with the contraction value of 39.6% at day 12 (Tables 5, 6). The results of hydroxyproline estimation were in accord with the data those obtained from both incision and excision wound models (Table 7).

Histopathologically, well-considered re-modeling, particularly re-epithelization was detected in the reference, MeOH and aqueous extracts treated groups and lesser in the n-hexane, ethyl acetate and diethyl ether extracts treated groups. In comparison with these groups, limited re-modeling was noticed in the vehicle, and negative control groups (Table 8). Histopathological results are supported with figures (Figure 1), which stained with HE and VG.

According to the published literatures, *Campanula* species were reported to have antiallergic, antiphlogistic, antioxidant, spasmolytic, antiviral, cytotoxic, antinociceptive and antimicrobial properties (4-7). In a previous study, the antinociceptive potential of *C. punctata* extract were examined in mice. *C. punctata* extract administered orally (200 mg/kg) showed an antinociceptive effect as measured by the tail-flick and hot-plate tests. In addition, *C. punctata* extract attenuated the writhing numbers in the acetic acid-induced writhing test. The results suggested that *C. punctata* extract showed an antinociceptive property, which may be mediated by α2-adrenergic receptor, but not opioidergic, and serotoninergic receptors (6). In the phytochemical studies on *Campanula* species, it was revealed that delphinidin-3-rutinoside-7-(tri-p-hydroxybenzoyl)triglucoside) was isolated from *C. medium* (19). Phenylpropanoid and flavonoid derivatives, barbatosides and barbatoflavans were isolated from the whole plant of *C. barbata*, and barbatoflavan was found to possess DPPH* scavenging activity (8). Furthermore, quercetin-3-O-glucoside, quercetin-3-O-rutinoside, kaempferol-3-O-glucoside, lobetinol (9-O-β-D-glucopyranosyl-2,10-tetradecadien-4,6-diyne-8,14-diol) and lobetol (2,10-tetradecadien-4,6-diyn-8,9,14-triol), were isolated from the MeOH extract of *C. alliariifolia*. The MeOH extract was shown to have antioxidant capacity. Lobetol and lobetol showed significant antioxidant activity more than both MeOH extract and other purified compounds (5).

Flavonoids are the group of compounds that have diverse beneficial activities and antioxidant effects. These type of compounds exhibits *in vitro* and *in vivo* anti-inflammatory potential (20). Recently, scientists have proven that some antioxidants have anti-inflammatory and wound healing properties. In wound healing process, they have capacity to scavenge free radicals (21). Furthermore, they have capacity to block inflammation by lowering the activation of inflammatory signals. Indeed, certain flavonoids are potent inhibitors of the production of prostaglandins. Studies have shown that this effect is due to flavonoid inhibition of key enzymes such as lipoxygenase, phospholipase, and cyclooxygenase. Flavonoids also inhibit phosphodiesterases (22).

**CONCLUSION**

According to the results the significant anti-inflammatory and wound healing activities of the MeOH extract of *C. lyrata* subsp. *lyrata* could be attributed to the flavonoid content of the plant. The present research confirms the traditional utilization of *Campanula lyrata* subsp. *lyrata*. 

antinociceptive and antimicrobial properties antiallergic, antiphlogistic, antioxidant, stained with HE and VG. supported with figures (Figure 1), which in the vehicle, and negative control groups which may be mediated by extract showed an antinociceptive property, these groups, limited re-modeling was noticed extracts treated groups. In comparison with punctata numbers in the acetic acid-induced writhing extract examined in mice. Studies have shown that this effect is due to lipoxygenase, phospholipase, and antioxidant effects. These type of compounds to scavenge free radicals. Furthermore, in wound healing process, they have capacity to inactivate inflammatory and wound healing properties. flavonoid derivatives, barbatosides and species were reported to have Campanula from Campanula P. phenylpropanoid and α-2-adrenergic Punctata (4-7). In a previous study, the antinociceptive strength value of 39.6% at day 12 (Tables 5, 6). The MeOH extract of Campanula lyrata was shown to have antioxidant activity more than both significant antioxidant activity more than both capacity. Lobetyol and lobetyolin showed extract was shown to have antioxidant effect of the extracts of Campanula C. lyrata C. punctata 7). In wound healing process, they have capacity from MeOH extract and other purified compounds significant wound healing activity on the was also evaluated. Ointment formulation from MeOH extract of Campanula C. lyrata. From the results, it was found that the MeOH extract of Campanula was also evaluated. Ointment formulation material Dose (mg/kg) Swelling thickness (x 10^-2 mm)± S.E.M. (Inhibition%) 0 min 6 min 12 min 18 min 24 min 30 min Control 100 5.0±0.8 8.8±1.4 15.3±1.8 16.1±0.9 22.1±1.3 26.9±1.8 12 min 15.3±1.1 19.6±1.9 23.5±1.6 21.9±1.3 18 min n-Hexane extract 200 4.5±0.6 8.5±1.3 13.7±1.4 15.3±1.1 19.2±1.2 22.5±1.4 10.0 12 min 4.9±0.7 9.5±1.2 12.8±1.5 14.5±1.6 20.5±1.2 27.8±1.6 8.0 18 min Diethyl ether extract 100 4.4±1.4 9.0±1.1 16.4±1.2 16.2±1.3 21.4±1.8 23.1±1.5 12.0 10 min 4.5±0.9 8.2±0.8 14.8±1.7 14.8±1.5 18.9±1.3 22.5±1.1 EtOAc extract 200 4.0±0.9 7.6±1.0 16.8±1.3 15.6±1.1 17.6±0.9 25.1±2.2 10.0 10 min 4.2±1.5 7.2±1.6 14.9±1.6 13.9±1.5 19.6±1.6 20.6±0.7 12.0 15 min MeOH extract 200 5.1±0.9 8.3±0.9 11.5±1.3 13.3±1.0 16.5±1.5 19.4±1.2 16.0 10 min 4.3±0.7 7.6±1.5 18.0±1.9 17.4±1.2 25.1±1.4 24.1±1.6 14.0 15 min Aqueous extract 100 4.8±0.8 7.8±1.6 15.2±1.2 17.1±1.2 20.5±1.1 23.8±1.5 11.4 10 min 3.8±0.4 5.8±0.7 10.3±0.9 12.0±1.1 13.4±0.7 17.4±0.9 7.2 15 min Indomethacin 10 3.8±0.4 5.8±0.7 10.3±0.9 12.0±1.1 13.4±0.7 17.4±0.9 (24.0)* (34.1)* (32.7)* (25.5)* (39.4)** (35.3)**

Table 2. Effect of the extracts from Campanula lyrata subsp. lyrata on serotonin-induced paw edema in mice

S.E.M.: Standard error of the mean
*p<0.05. **p<0.01. *** p<0.001 significant from the control
Table 3. Effect of the extracts from *Campanula lyrata* subsp. *lyrata* against TPA-induced ear edema in mice as measurement swelling thickness and weight measurement of edema

| Test samples          | Dose (mg/ear) | Swelling thickness (µm) ± SEM | Inhibition % | Weight edema (mg) ± SEM | Inhibition % |
|-----------------------|---------------|-------------------------------|--------------|-------------------------|--------------|
| Control               |               | 342.7 ± 28.3                  |              | 30.6 ± 3.0              |              |
| *n*-Hexane extract    | 0.5           | 328.5 ± 23.8                  | 4.1          | 24.3 ± 2.9              | 20.6         |
| Diethyl ether extract | 0.5           | 298.3 ± 27.6                  | 12.9         | 31.2 ± 3.2              |              |
| EtOAc extract         | 0.5           | 338.6 ± 30.7                  | 1.19         | 32.6 ± 3.4              |              |
| MeOH extract          | 0.5           | 285.0 ± 26.4                  | 16.8         | 24.4 ± 2.8              | 20.3         |
| Aqueous extract       | 0.5           | 336.5 ± 22.8                  | 1.8          | 29.0 ± 2.6              | 5.2          |
| Indomethacin          | 0.5           | 100.6 ± 12.5                  | **70.6***    | 13.9 ± 1.5              | **54.6***    |

S.E.M.: Standard error of the mean
* p<0.05. **p<0.01. *** p<0.001 significant from the control

Table 4. Inhibitory effect of the extracts from *Campanula lyrata* subsp. *lyrata* on acetic acid-induced increase in capillary permeability

| Material               | Dose (mg/kg) | Evans blue concentration (µg/mL) ± SEM | Inhibition (%) |
|------------------------|--------------|----------------------------------------|----------------|
| Control                |              | 12.82 ± 1.16                           |                |
| *n*-Hexane extract     | 100          | 11.81 ± 0.91                           | 7.9            |
|                        | 200          | 11.65 ± 0.78                           | 9.1            |
|                        | 100          | 12.95 ± 1.20                           | -              |
| Diethyl ether extract  | 200          | 11.97 ± 1.12                           | 6.6            |
|                        | 100          | 10.86 ± 0.99                           | 15.3           |
| EtOAc extract          | 200          | 10.33 ± 0.87                           | 19.4           |
|                        | 100          | 9.81 ± 0.86                            | 23.5           |
| MeOH extract           | 200          | 8.74 ± 1.11                            | **31.8**       |
| Aqueous extract        | 100          | 12.60 ± 1.08                           | 1.7            |
|                        | 200          | 12.38 ± 1.13                           | 3.4            |
| Indomethacin           | 10           | 6.08 ± 0.52                            | **52.6***      |

S.E.M.: Standard error of the mean
* p<0.05. **p<0.01. *** p<0.001 significant from the control

Table 5. Effect of the extracts from *Campanula lyrata* subsp. *lyrata* on incision wound model

| Material                | Statistical Mean ± S.E.M. | (Tensile strength %) |
|-------------------------|---------------------------|----------------------|
| Vehicle                 | 10.08 ± 1.88              | 1.3                  |
| Negative Control        | 9.95 ± 1.75               | -                    |
| *n*-Hexane extract      | 10.80 ± 1.92              | 7.1                  |
| Diethyl ether extract   | 10.44 ± 2.02              | 3.6                  |
| EtOAc extract           | 10.60 ± 1.26              | 5.2                  |
| MeOH extract            | 12.79 ± 0.79              | **26.9**             |
| Aqueous extract         | 11.41 ± 1.61              | 13.2                 |
| Madecassol®             | 15.38 ± 0.67              | **52.6***            |

* : p < 0.05; ** : p < 0.01; *** : p < 0.001; S.E.M.: Standard error of the mean
Percentage of tensile strength values: Vehicle group was compared to Negative control group; Extracts were compared to Vehicle group
Table 6. Effect of the extracts from *Campanula lyrata* subsp. *lyrata* on excision wound model

| Material                  | 0  | 2   | 4    | 6    | 8    | 10   | 12   |
|---------------------------|----|-----|------|------|------|------|------|
| Vehicle                   | 19.52 ± 2.13 | 17.27 ± 1.59 | 15.93 ± 1.50 | 14.28 ± 1.19 | 10.98 ± 1.27 | 7.42 ± 1.14 | 3.33 ± 0.47 |
| Negative Control           | 19.46 ± 2.05 | 17.38 ± 1.62 | 16.09 ± 1.81 | 14.91 ± 1.60 | 12.35 ± 1.31 | 8.14 ± 1.22 | 3.62 ± 1.14 |
| *n*-Hexane extract        | 19.39 ± 2.17 | 16.82 ± 1.46 | 15.75 ± 2.04 | 13.48 ± 1.73 | 10.26 ± 1.48 | 7.10 ± 1.24 | 2.91 ± 0.32 |
| Diethyl ether extract     | 19.51 ± 2.04 | 17.34 ± 1.36 | 16.44 ± 1.90 | 14.02 ± 1.78 | 11.23 ± 1.41 | 7.35 ± 1.23 | 3.40 ± 0.89 |
| EtOAc extract             | 19.28 ± 2.15 | 16.95 ± 1.51 | 15.81 ± 2.03 | 13.77 ± 1.24 | 10.06 ± 1.43 | 6.49 ± 1.04 | 3.01 ± 0.39 |
| MeOH extract              | 19.45 ± 2.24 | 15.91 ± 1.13 | 14.13 ± 1.27 | 12.31 ± 1.07 | 8.22 ± 1.04 | 5.01 ± 0.85 | 2.01 ± 0.21 |
| Aqueous extract           | 19.38 ± 2.06 | 16.75 ± 1.47 | 15.22 ± 1.76 | 13.56 ± 1.28 | 9.01 ± 1.02 | 6.13 ± 0.93 | 2.63 ± 0.37 |
| Madecassol®               | 19.50 ± 1.95 | 14.86 ± 1.29 | 13.18 ± 1.45 | 9.17 ± 0.57 | 3.49 ± 0.81 | 1.37 ± 0.39 | 0.00±0.00 |

*: p < 0.05; **: p < 0.01; ***: p < 0.001; S.E.M.: Standard error of the mean

Percentage of contraction values: Vehicle group was compared to Negative control group; Extracts were compared to Vehicle group.
Table 7. Effects of the test ointments prepared from the extracts of *Campanula lyrata* subsp. *lyrata* on hydroxyproline content

| Material                  | Hydroxyproline (µg/mg) ± S.E.M. |
|---------------------------|---------------------------------|
| Vehicle                   | 11.25 ± 1.88                    |
| Negative Control          | 9.14 ± 1.64                     |
| *n*-Hexane extract        | 14.27 ± 1.49                    |
| Diethyl ether extract     | 11.61 ± 1.93                    |
| EtOAc extract             | 15.16 ± 1.75                    |
| MeOH extract              | 26.41 ± 0.96*                   |
| Aqueous extract           | 20.46 ± 1.78                    |
| Madecassol®               | 47.22 ± 0.51***                 |

* : p < 0.05; ** : p < 0.01; *** : p < 0.001; S.E.M.: Standard error of the mean

Figure 1. Histopathological view of wound healing and epidermal/dermal re-modeling in the vehicle, negative control, extract ointments and Madecassol® administered animals.

Skin sections show the hematoxylin & eosin (HE) stained epidermis and dermis in A, and the dermis stained with Van Gieson (VG) in B. The original magnification was x 100 and the scale bars represent 120 µm for figures in A, and the original magnification was x 400 and the scale bars represent 40 µm for B. Data are representative of 6 animal per group. 1) Vehicle; 2) Negative Control; 3) *n*-Hexane extract; 4) Diethyl ether extract; 5) EtOAc extract; 6) MeOH extract; 7) Aqueous extract; 8) Reference
### Table 7. Effects of the test ointments prepared from the extracts of *Campanula lyrata* subsp. *lyrata* on hydroxyproline content

| Material               | Hydroxyproline (µg/mg) ± S.E.M. |
|------------------------|----------------------------------|
| Vehicle                | 11.25 ± 1.88                     |
| Negative Control       | 9.14 ± 1.64                      |
| n-Hexane extract       | 14.27 ± 1.49                     |
| Diethyl ether extract  | 11.61 ± 1.93                     |
| EtOAc extract          | 15.16 ± 1.75                     |
| MeOH extract           | 26.41 ± 0.96*                    |
| Aqueous extract        | 20.46 ± 1.78                     |
| Madecassol®            | 47.22 ± 0.51***                  |

* : p < 0.05; ** : p < 0.01; *** : p < 0.001; S.E.M.: Standard error of the mean

### Table 8. Wound healing processes and healing phases of the experimental group animals

| Groups              | S       | U       | RE     | FP     | CD     | MNC    | PMN    | NV     | I       | P       | R       |
|---------------------|---------|---------|--------|--------|--------|--------|--------|--------|---------|---------|---------|
| Vehicle             | ++/+++  | +/++   | +      | ++/+++ | ++/+++ | ++     | ++     | ++/+++ | ++/+++  | ++/+++  | ++/+++  |
| Negative Control    | ++/+++  | +/++   | -/+    | +++    | ++/+++ | ++/+++ | ++     | +++    | ++/+++  | ++      | +++     |
| n-Hexane extract    | ++      | -/+    | ++/++  | +++    | ++/+++ | ++/+++ | ++     | ++     | ++/+++  | ++      | ++/+++  |
| Diethyl ether extract| ++/+++ | +      | ++/++  | ++++/++| +++/++ | ++/+++ | ++     | ++     | ++/++++ | ++      | ++/++++ |
| EtOAc extract       | ++      | +      | ++/++  | +++    | ++     | ++     | +++    | ++     | +++     | ++/+++  | ++/+++  |
| MeOH extract        | +       | -      | ++     | +++    | ++     | ++     | +      | ++     | +       | ++/+++  | ++      |
| Aqueous extract     | +/-     | -      | ++/++  | +++    | ++     | +++    | +      | ++     | +++     | ++      | ++      |
| Madecassol®         | +       | -      | ++     | +++    | ++     | +++    | +      | ++     | +       | ++      | ++      |

HE and VG stained sections were scored as mild (+), moderate (+++) and severe (++++) for epidermal and/or dermal re-modeling. S: Scab, U: Ulcus, RE: Re-epithelization, FP: Fibroblast proliferation, CD: Collagen depositions, MNC: Mononuclear cells, PMN: Polymorphonuclear cells, NV: Neovascularization, I: Inflammation phase, P: Proliferation phase, R: Re-modeling phase.
REFERENCES

1. Damboldt J, Campanula L. In: Flora of Turkey and The East Aegean Islands, Vol. 6, Ed: P.H. Davis, pp. 2-64, Edinburgh University Press, Edinburgh, 1988.
2. Roi J, Traite des Plantes Medicinales Chinoises, Encyclopedie Biologique, Paris 1955.
3. Baytop T, Theraphy with Medicinal Plants in Turkey (past and present), Nobel Press, Istanbul, pp. 371, 1999.
4. Benli M, Bingöl U, Geven F, Güney K, Yiğit N, An investigation on the antimicrobial activity of some endemic plant species from Turkey, Afr J Biotechnol 2008; 7; 1-5.
5. Dumlulu MU, Gürkan E, Tuzlacı E, Chemical composition and antioxidant activity of Campanula alliiariifolia, Nat Prod Res 22(6), 477-482, 2008.
6. Park SH, Sim YB, Lim SS, Kim JK, Lee JK, Suh HW, Antinociception effect and mechanism of Campanula punctata extract in mouse, Korean J Physiol Pharmacol 14(5), 285-289, 2010.
7. Tosun G, Kahrıman N, Coşkuncelebi K, Genç H, Karaoğlu SA, Yaylı N, Chemical composition and biological activity of the essential oil of Campanula olympica Boiss, Asian J Chem 23(6), 2389-2391, 2011.
8. Cuendet M, Potterat O, Kurt H, Flavonoids and phenylpropanoid derivatives from Campanula barbata, Phytochemistry 56, 631-636, 2001.
9. Yaylı N, Yıldırım N, Doğan N, Usta A, Altunl L, Triterpenes from Campanula lactiflora, J Asian Nat Prod Res 7(5), 771-775, 2005.
10. Yesilada E, Küpeli E, Berberis crataegina DC. Root exhibits potent anti-inflammatory, analgesic and febrifuge effects in mice and rats, J Ethnopharmacol 79, 237-248, 2002.
11. Kasahara Y, Hikino H, Tsurufiji S, Watanabe M, Ohuchi K, Antiinflammatory actions of ephedrines in acute inflammations, Planta Med 51, 325-331, 1985.
12. De Young LM, Kheifets JB, Ballaron SJ, Young JM, Edema and cell infiltration in the phorbol ester treated mouse ear are temporarily separate and can be differently modulated by pharmacologic agents, Agents Actions 26, 335-341, 1989.
13. Yesilada E, Küpeli, E, Clematis vitalba L. aerial part exhibits potent anti-inflammatory, antinoceceptive and antipyretic effects, J Ethnopharmacol 110, 504-515, 2007.
14. Süntar I, Küpeli Akkol E, Keles H, Yesilada E, Sarker SD, Arroo R, Baykal T, Efficacy of Daphne oleoides subsp. kurdica used for wound healing: Identification of the active compounds through bioassay guided isolation technique, J Ethnopharmacol 141, 1058-1070, 2012.
15. Degim Z, Çelebi N, Sayan H, Babül A, Erdoğan D, Take G, An investigation on skin wound healing in mice with a taurine-chitosan gel formulation, Amino Acids 2002; 22; 187-198.
16. Vinegar R, Schreiber W, Hugo R, Biphasic development of carrageenan edema in rats, J Pharmacol Exp Ther 166, 96-103, 1969.
17. Olajide OA, Awe SO, Makinde JM, Effects of the aqueous extract of Bridelia ferruginea stem bark on carrageenan-inducededema and granuloma tissue formation in rats and mice, J Ethnopharmacol 66, 113-117, 1989.
18. Murakami A, Nakamura Y, Torikai K, Inhibitory effect of citrus nobiletin on phorbol ester-induced skin inflammation, oxidative stress, and tumor promotion mice, Cancer Res 60, 5059-5066, 2000.
19. Brandt K, Kondo T, Aoki H, Goto T, Structure and bio-synthesis of anthocyanins in flowers of Campanula, Phytochemistry 33, 209-212, 1993.
20. Manthey JA, Guthire N, Grohman K, Biological properties of Citrus flavonoids pertaining to cancer and inflammation, Curr Med Chem 8, 135-153, 2001.
21. Shetty S, Udupa S, Udupa L, Evaluation of antioxidant and wound healing effects of alcoholic and aqueous extract of Ocimum sanctum Linn in rats, Evid-Based Compl Alt 5, 95-101, 2008.
22. Manthey JA, Biological properties of flavonoids pertaining to inflammation, Microcirculation 7, 29-34, 2000.

Received: 23.10.2014
Accepted: 15.01.2015